preclinical evidence

Unravelling the syndrome of age associated diseases 2: Targeting autoimmunity with anti-CD20 antibodies to reduce age-associated diseases

The antibody Rituximab that was originally used to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia was found to be effective for all autoimmune diseases studied so far. This raises the…